Bladder Cancer, Version 3.2024-Reference-Cited by-同舟云学术

Bladder Cancer, Version 3.2024

Published:2024-05 Issue:4 Volume:22 Page:216-225
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Flaig Thomas W.¹,Spiess Philippe E.²,Abern Michael³,Agarwal Neeraj⁴,Bangs Rick⁵,Buyyounouski Mark K.⁶,Chan Kevin⁷,Chang Sam S.⁸,Chang Paul⁹,Friedlander Terence¹⁰,Greenberg Richard E.¹¹,Guru Khurshid A.¹²,Herr Harry W.¹³,Hoffman-Censits Jean¹⁴,Kaimakliotis Hristos¹⁵,Kishan Amar U.¹⁶,Kundu Shilajit¹⁷,Lele Subodh M.¹⁸,Mamtani Ronac¹⁹,Mian Omar Y.²⁰,Michalski Jeff²¹,Montgomery Jeffrey S.²²,Parikh Mamta²³,Patterson Anthony²⁴,Peyton Charles²⁵,Plimack Elizabeth R.¹¹,Preston Mark A.²⁶,Richards Kyle²⁷,Sexton Wade J.²,Siefker-Radtke Arlene O.²⁸,Stewart Tyler²⁹,Sundi Debasish³⁰,Tollefson Matthew³¹,Tward Jonathan⁴,Wright Jonathan L.³²,Cassara Carly J.³³,Gurski Lisa A.³³

Affiliation:

1. University of Colorado Cancer Center

2. Moffitt Cancer Center

3. Duke Cancer Institute

4. Huntsman Cancer Institute at the University of Utah

5. Patient Advocate

6. Stanford Cancer Institute

7. City of Hope National Medical Center

8. Vanderbilt-Ingram Cancer Center

9. The UChicago Medicine Comprehensive Cancer Center

10. UCSF Helen Diller Family Comprehensive Cancer Center

11. Fox Chase Cancer Center

12. Roswell Park Comprehensive Cancer Center

13. Memorial Sloan Kettering Cancer Center

14. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

15. Indiana University Melvin and Bren Simon Comprehensive Cancer Center

16. UCLA Jonsson Comprehensive Cancer Center

17. Robert H. Lurie Comprehensive Cancer Center of Northwestern University

18. Fred & Pamela Buffett Cancer Center

19. Abramson Cancer Center at the University of Pennsylvania

20. Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

21. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

22. University of Michigan Rogel Cancer Center

23. UC Davis Comprehensive Cancer Center

24. St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center

25. O’Neal Comprehensive Cancer Center at UAB

26. Dana-Farber/Brigham and Women’s Cancer Center

27. University of Wisconsin Carbone Cancer Center

28. The University of Texas MD Anderson Cancer Center

29. UC San Diego Moores Cancer Center

30. The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

31. Mayo Clinic Comprehensive Cancer Center

32. Fred Hutchinson Cancer Center

33. National Comprehensive Cancer Network

Abstract

Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non–muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guérin (BCG)–unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.

Publisher

Harborside Press, LLC

Link

https://jnccn.org/downloadpdf/journals/jnccn/22/4/article-p216.xml

Reference47 articles.

1. Cancer statistics, 2024;Siegel RL,2024

2. Bladder cancer: bladder cancer

3. Bladder cancer: diagnosis and treatment;DeGeorge KC,2017

4. Diabetes mellitus and the risk of bladder cancer: a PRISMA-compliant meta-analysis of cohort studies;Xu Y,2017

5. Bladder cancer incidence and mortality: a global overview and recent trends;Antoni S,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOX7 inhibits the malignant progression of bladder cancer via the DNMT3B/CYGB axis;Molecular Biomedicine;2024-09-04

2. Development and Validation of a Contrast-Enhanced US VI-RADS for Evaluating Muscle Invasion in Bladder Cancer;Radiology;2024-09-01

3. A Vesical Imaging Reporting and Data System for Contrast-enhanced US;Radiology;2024-09-01

4. The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria;ESMO Open;2024-09

5. Does radical cystectomy still have a role in BCG-unresponsive nonmuscle invasive bladder cancer?;Current Opinion in Urology;2024-08-20